Drugs / hALK.CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06803875 | Jan 2025 → Dec 2027 expected | neuroblastoma | Roberto Chiarle | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hALK.CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06803875 ↗ |
| Modality | Cell therapy | “Autologous chimeric antigen receptor T cells” NCT06803875 ↗ |
| Target | ALK | “targeting the human Anaplastic Lymphoma Kinase (ALK) receptor” NCT06803875 ↗ |